Sharing your child’s journey with Sanfilippo can advance new treatments Because Sanfilippo Syndrome is rare, researchers need more information directly from patients and their families to understand the condition. Your child’s progression, symptoms and health...
Collaboration
Advancing the Understanding of Special Education and Therapeutic Needs of Children with Neurodegenerative Disorders
The challenges of the pandemic shined a light on the critical role of special educators and rehabilitative therapists to protect the skills of children’ with neurodegenerative disorders. This academic publication and white paper provides teachers with a guide for...
Cure Sanfilippo lends support to multiple provisions of Cures 2.0 Act
The 21st Century Cures 2.0 Act legislation from U.S. Representatives Diana DeGette (D-Colorado) and Fred Upton (R-Michigan) could have a profound impact on the speed of therapy development and diagnostic access for patients with rare diseases. "Many organizations have...
Cure Sanfilippo agrees: The need to use surrogate biomarkers in an accelerated drug approval pathway for diseases like Sanfilippo
A powerful article from Dr. Emil D. Kakkis outlines the critical need for use of surrogate biomarkers in an accelerated drug approval pathway for diseases like Sanfilippo syndrome. In the article, "Aduhelm’s accelerated approval offers a promising roadmap for rare...
Research: Lysosomal storage disorders with altered heparan sulfate metabolism lead to dopamine-dependent autistic behaviors in Sanfilippo mouse models
A research project co-funded by Cure Sanfilippo Foundation and Sanfilippo Children's Foundation (Australia) recently published its findings, "Altered heparan sulfate metabolism during development triggers dopamine-dependent autistic-behaviours in models of lysosomal...
History being made: ScreenPlus, the largest U.S. newborn screening study, includes Sanfilippo
History is being made! Starting this week, newborns in the largest ever U.S. newborn screening study, ScreenPlus, are being screened for Sanfilippo syndrome Type B! Addition of Sanfilippo Type A will follow in the coming months! Why invest in Newborn Screening...
Cure Sanfilippo supports North Carolina legislation HB 736 to expand state newborn screening
Cure Sanfilippo Foundation has joined other rare disease patient organizations in thanking the North Carolina House of Representatives for its leadership in passing HB 736, Timely Updates to Newborn Screening Program, and calling for the Senate to also pass the...
Cure Sanfilippo joins in calling Congress to support The BENEFIT Act
Cure Sanfilippo Foundation has signed-on to a stakeholder letter that calls for the U.S. Congress to support the Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act (S. 373), sponsored by U.S. Senators Roger Wicker (R-MS) and Amy Klobuchar...
Newborn screening pilot ScreenPlus that includes Sanfilippo Type A and B
When children with a rare disease are diagnosed at birth, they have the greatest opportunity to receive timely, approved treatments or participate in clinical trials that can provide them better quality of life and less pain and suffering. Early diagnosis and...